Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Donna Carey who wrote (1316)	10/24/1998 11:18:00 AM
From: DavidCG	Respond to of 2135

Thanks Donna, I don't watch that much CNBC after hours. I'm glad you caught this and brought it to our attention. -DavidCG

To: Donna Carey who wrote (1316)	10/24/1998 11:56:00 AM
From: margaret foley	Read Replies (1) \| Respond to of 2135

On the yahoo board, the Joe K. Story was mentioned and then someone else said that it was not so. Did you hear it yourself? Thank you. Also, did you read the yahoo message by Folkman and O'Brien? *********************** Message 3853 of 3856 October 22, 1998 ************************ In response to Gigabucks 53 Recombinant mouse endostatin produced by E. coli continues to be used by us to regress tumors in mice. In fact, we have just completed a long-term study in which human prostate cancer cells implanted orthotopically in the prostates of immunodeficient mice regress from a large tumor mass to a microscopic dormant size or completely (depending upon dose and schedule). These results confirm Nature, Nov 27, 1997, will be presented in abstract form at the American College of Surgeons in Orlando 10/26/98, and will then be submitted for publication. Judah Folkman, M.D.and Michael O'Reilly, M.D. Children's Hospital, Boston, Mass.